nav-left cat-right
cat-right

Validated biomarkers will drive personalized medic...

Biomarkers will be accepted as predicted tools, but their clinical usefulness needs to be understood first, according to personalized medicine expert. Coordinating personalized medicine on an international level, Dr Edward Abrahams, Executive Director of the Personalized Medicine Coalition believes that biomarkers will eventually impact all disease areas. “When they were validated, and when it can be understood how...

Norwich company joins cancer fight

A new company based on the Norwich Research Park has joined the fight against MRSA and cancer. Researchers at the John Innes Centre near Norwich have launched a new company, Inspiralis, based around their expertise in ‘DNA topoisomerases’. These are a group of enzymes that help DNA molecules to unravel and wind up properly and not to become tangled during replication. Inspiralis co-founder Nicolas Burton said:...

DNA with a twist: New company to search for cancer...

A new company has joined the fight against MRSA and cancer. Researchers at the John Innes Centre (Norwich) have launched a new company, Inspiralis Ltd, based around their expertise in DNA topoisomerases – a group of enzymes that help DNA molecules to unravel and wind up properly and not to become tangled during replication. “DNA becomes tangled as a result of various cellular processes, such as replication, which...

New drug target leaves lung cancer cells alone, lo...

It seems even tumour cells can get lonely; scientists have discovered that by cutting off a key gene, lung cancer tumour cells are left ‘homeless’ and they can’t survive on their own. The gene in question is called 14-3-3zeta and it can now be considered a potential target for selective anticancer drugs, according to Professor Haian Fu at the Emory University School of Medicine. These latest research results...

Michael J. Fox Foundation Awards $4.4 Million for ...

NEW YORK, Dec. 18 /PRNewswire-USNewswire/ — The Michael J. Fox Foundation has awarded $4.4 million to jump-start the development of a new class of symptomatic Parkinson’s disease drugs targeting glutamate receptor mGluR4. The funding was awarded to a multidisciplinary team of researchers led by Jeffrey Conn, PhD, of Vanderbilt University under the Foundation’s LEAPS (Linked Efforts to Accelerate...

Profiling of Tumor Tissue Slices is Awarded Prize

Novel drug screening tool based on the Bionas® 2500 analyzing system wins silver medal in European business plan contest Rostock, Germany, November 26, 2007 / b3c newswire / – Bionas GmbH, a specialist for in vitro profiling the metabolic activity of cells, announced that Prof. Pedro Mestres of the Saarland University (Homburg/Saar, Germany) has been awarded the second prize in the business plan contest 1,2,3 GO for...
Page 20 of 28« First...10...1819202122...Last »